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Objective: Liver ﬁbrosis results from the wound healing response to chronic liver damage. Advanced liver
ﬁbrosis results in cirrhosis and liver failure, and liver transplantation is often the only option for effective
therapy; however, the shortage of available donor livers limits this treatment. Thus, new therapies for
advanced liver ﬁbrosis are essential.
Materials and methods: Amniotic ﬂuid contains an abundance of stem cells, which are derived from all
three germ layers of the developing fetus. These cells do not induce teratomas in vivo and do not pose any
ethical concerns. To generate liver ﬁbrosis models, male ICR mice were treated with CCl4 via oral gavage
for 4 weeks, and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate trans-
aminase, and albumin were higher than in the control group following chemical induction. To assess the
potential of amniotic-ﬂuid-derived stem cells (mAFSCs) to ameliorate liver ﬁbrosis in vivo, mAFSCs were
isolated from amniotic ﬂuid of 13.5-day-old transgenic mice, which globally express the ﬂuorescent
protein, enhanced green ﬂuorescent protein (EGFP), for tracing purposes (EGFP-mAFSCs). Single cells
were injected via the mesentery (1  106 cells/mouse) of transplanted mice with liver ﬁbrosis.
Results: Four weeks after EGFP-mAFSC transplantation, the serum glutamate oxaloacetate transaminase,
glutamate pyruvate transaminase, and albumin levels of recipient mice in the EGFP-mAFSC-injected
group were signiﬁcantly decreased when compared with mice in the saline-injected group. Addition-
ally, ﬁbrotic tissues were evaluated using Masson's trichrome staining 4 weeks after cell transplantation.
Shrinkage of the ﬁbrotic area was observed in the EGFP-mAFSC-injected group. The tissue-repair effects
were also conﬁrmed by hydroxyproline content analysis.
Conclusion: The possible repair mechanism from our data revealed that EGFP-mAFSCs may fuse with the
recipient liver cells. Overall, EGFP-mAFSCs can ameliorate liver ﬁbrosis in mice, thus providing insight
into the future development of regenerative medicine.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.333, Taiwan.
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Five percent of the global population (300 million) has chronic
liver disease and 2million patients have died due to liver disease. In
Taiwan, carriers of hepatitis have reached 15e20% of the population
and hepatitis ranks seventh among the top 10 causes of death. Liver
ﬁbrosis is a consequence of chronic liver disease resulting fromviral
infections, alcohol abuse, drug overdose, and dietary habits.by Elsevier Taiwan LLC. All rights reserved.
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matrix (ECM) to compensate for the gaps resulting from damaged
hepatocytes formaintaining liver structure. Accumulation of ECM is
referred to as liver ﬁbrosis [1]. As a result, curing liver ﬁbrosis is an
essential health issue.
Due to a lack of suitable medications, liver ﬁbrosis easily con-
verts into liver cirrhosis. Liver transplantation is an option; how-
ever, there is a lack of donors, which leads to a high mortality rate.
Hence, an alternative approach to cure liver ﬁbrosis needs to be
investigated. There are many sources of cells that have been re-
ported to alleviate liver ﬁbrosis/cirrhosis successfully, including
umbilical-cord-derived cells [2,3], bone-marrow-derived cells
[4e6], and hepatic stem/progenitor cells mature hepatocytes [7].
Such cell sources can be retained in the liver for a long time and
reduce collagen scarring and improve liver function, as shown by
blood biochemistry values [8e10]. It has been demonstrated that
undifferentiated stem/progenitor cells have better therapeutic ef-
ﬁcacy in repairing liver ﬁbrosis and are retained in a higher quan-
tity in the liver than differentiated cells [11,12]. Donor
undifferentiated cells may elevete the content of matrix metal-
loproteinase (MMP)-2, MMP-9 and MMP-14 [13,14] to degrade the
collagen in ﬁbrotic scarring [13,15]. Donor cells hold the properties
of antioxidants to alleviate liver ﬁbrosis [16].
It is difﬁcult to retrieve sufﬁcient stem/progenitor cells from
patients, hence, a source with a large quantity of cells is needed for
transplantation. Amniotic ﬂuid can be collected through amnio-
centesis, which is thought to supply abundant progenitor cell
source of cells shed from the fetus during pregnancy and holds
great potential for therapeutic use [17].
Intra-liver injection of stem cells results in an uneven distri-
bution to the liver and causes bleeding during injection [18].
Splenic injection is another option to infuse stems cells; however,
the therapeutic effect and survival rate is low compared to other
routes of transplantation [12]. Stem cells are easily trapped in lung
capillaries during tail vein injection [19]. Peritoneal injection of
stem cells results in peritonitis and adhesions. Portal vein injection
is superior to vena caudalis injection or other routes [20]. Thus,
portal vein injection of stem cells is a universal method of trans-
plantation. Cell infusion via the portal vein results in an even
distribution in the liver and does not lead in liver injury. Of note,
we found that portal vein injection can cause serious bleeding and
result in injury. Thus, we have transplanted the cells through the
mesentery (upstream of the portal vein) to avoid an abundant loss
of blood. There are no reports demonstrating amniotic-ﬂuid-
derived stem cell amelioration of liver ﬁbrosis/cirrhosis. We
transplanted enhanced green ﬂuorescent protein (EGFP)-mouse
amniotic-ﬂuid-derived stem cells (mAFSCs) to assess the efﬁcacy
of recovery from CCl4-induced liver ﬁbrosis in a Ds-red (Discosoma
sp.)-harboring mouse model and determined how the donor cells
improved liver ﬁbrosis syndrome.
Materials and methods
Animals
Ubiquitously-expressed Ds-red-harboring ICR mice and EGFP-
harboring ICR mice were bred and maintained in the Animal
Reproductive Technology Laboratory of the Department of Animal
Science and Technology, at the National Taiwan University.
The mice were housed under standard conditions, and all experi-
mental procedures were approved by the Institutional Animal Care
and Use Committee. Eight-week-old Ds-red-harboring ICR male
mice were utilized to establish a liver ﬁbrosis mouse model. EGFP-
harboring ICR pregnant mice were used to retrieve mAFSCs for
transplantation.Production of EGFP- and Ds-red-expressing transgenic mice
To track how the transplanted cells interact with liver ﬁbrosis
hepatocytes, EGFP- and Ds-red-expressing transgenic mice were
generated by means of pronuclear microinjection of ICR strain zy-
gotes with ScaIePstI DNA fragments, which are composed of b-actin
promoter-driven EGFP or red ﬂuorescent protein from pCX-EGFP or
pCX-Ds-red plasmids. Ubiquitously expressed EGFP or Ds-red was
successfully produced.
Collection of EGFP-harboring mAFSCs
EGFP-harboring mice (13.5 days pregnant) were anesthetized
with CO2 and sacriﬁced via cervical dislocation. Then, 70% alcohol
was used to disinfect the extirpated uterus, which was immersed in
2% fetal bovine serum (FBS) containing phosphate-buffered saline.
The uteri were sectioned and segregated, and each fetus from the
amniotic sacs was examined for EGFP signals. We then peeled the
amniotic membranes from the fetuses and amniotic ﬂuid was
collected. Amniotic ﬂuid was subsequently centrifuged at
12,000 rpm for 10 minutes. We resuspended the pellet in a-mini-
mal essential medium (MEM; Sigma, St. Louis, MO, USA) with 10%
FBS. A limiting dilution method was used and cells were seeded in
32-well plates. Fibroblast-shaped colonies were selected to culture
until conﬂuence. The cells were passaged in a dilution of 1:2 for
subsequent transplantation.
Examination of ﬂuorescence-activated cell sorting
Trypsin/EDTA (Gibco 25200; Los Angeles, CA, USA) was utilized
to detach the cells, which were then stained with CD44, stem cell
antigen 1 (Sca-1), and CD105 (eBioscience, San Diego, CA, USA),
ﬁxed, and examined using a ﬂuorescence-activated cell sorter
(FACSCalibur; Becton Dickinson, San Jose, CA, USA). To avoid false-
positive staining, isotypes were utilized as negative controls
(eBioscience).
Tri-lineage differentiation of mAFPCs
To verify the tri-lineage differentiation potential of mAFSCs,
osteogenic, adipogenic, and chondrogenic differentiation was
conducted. For adipogenic differentiation, mAFSCs were cultured
for 3 weeks in a-MEM with 10% FBS, 0.5 mM isobutyl-
methylxanthine (Sigma), 1 mM dexamethasone (Sigma), 10 mg/mL
insulin (Sigma), and 100 mM indomethacin (Sigma). Lipid droplets
were observed by staining with oil red O (Sigma). For osteogenic
differentiation, mAFSCs were cultured for 3 weeks in a-MEM with
10% FBS, 10 mM glycerolphosphate (Sigma), 50 mM ascorbic acid
(Sigma), and 0.1 mM dexamethasone. Mineralized bone matrix was
observed by staining with alizarin red S (Sigma). For chondrogenic
differentiation, mAFSCs were cultured for 3 weeks in a-MEM with
1% FBS, 50 mM ascorbic acid, 10 ng/mL transforming growth factor-
1, and 6.25 mg/mL insulin (R&D Systems, Minneapolis, MN, USA).
Proteoglycans were visualized with toluidine blue (Sigma) staining.
Establishment of liver ﬁbrosis mice
A liver ﬁbrosis model was produced using CCl4 [21]. The mice
were randomized and separated into three groups: wild-type; CCl4;
and oil control (n ¼ 6 per group). Ds-red-harboring ICR male mice
(8 weeks old) were treated with CCl4 (2 mL/kg) in sunﬂower oil
solution twice weekly. ICR mice (8 weeks old) were treated with
sunﬂower oil solution without CCl4 every week, and designated as
the pseudo-fed shame group to conﬁrm the feeding procedure did
not inﬂuence the results.
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The weights of individual mice were determined every week
during the 8-week test period.
Experimental design of AFSCs transplantation into the liver ﬁbrosis
model
The 8-week-old Ds-red-harboring ICR mice were administered
CCl4 (2 mL/kg). After 4 weeks, the mice were randomly divided into
two groups. One group underwent cell transplantation therapy,
while the other group was given PBS and served as a negative
control (n ¼ 6 each group). The other group was only given sun-
ﬂower oil instead of CCl4. Four weeks after the ﬁrst feeding, the
mice underwent sham surgery and were injected with PBS (nega-
tive control group). Eight weeks after the ﬁrst CCl4 feeding, the
mice were sacriﬁced. Blood and liver samples were collected to
determine the effect of cell transplantation on liver ﬁbrosis.
EGFP-mAFSCs were injected through mesenteric vessels
Anesthesia was established with 1.2% tribromoethanol (Avertin;
Sigma) intraperitoneally. The Ds-red-harboring mice were placed
in the supine position on the operating table, the hair on the
abdomen was shaved, and disinfected with alcohol. Using surgical
scissors to expose the abdominal muscles, the muscle layer was
transected. A mesenteric vessel was selected, clipped, and EGFP-
mAFSCs (1  106/100 mL; 100 mL/30 second) were injected using a
28G insulin needle (Fig. 1). After surgery, the remaining tissues
were restored to the anatomic position, the muscle and skin layers
were closed with sutures, and the surgical site was disinfected.
During the recovery period, red radiant light was used to maintain
the body temperature and sufﬁcient water was provided.
Detection of blood biochemical parameters
Before sacriﬁcing the mice, blood was collected from the retro-
orbital plexus and centrifuged at 12,000 rpm for 5minutes at 4C in
a refrigerated centrifuge to separate the serum. Glutamic oxalo-
acetic transaminase (GOT), glutamic pyruvic transaminase (GPT),
and albumin (ALB) were analyzed using commercial test strips (ALT
and AST Spotchem II reagent strips; Arkray, Kyoto, Japan) and the
use of an automatic blood analyzer (Spotchem EZ automated dry
chemistry analyzer; Arkray).Fig. 1. Mesentery injection of enhanced green ﬂuorescent protein-mouse amniotic-
ﬂuid-derived stem cells.Measurement of hydroxyproline
Approximately 70 mg of liver tissue was placed in a test tube
and homogenized, to which was added 700 mL 6N HCl at 120C
overnight for hydrolysis. After cooling, the sample was centrifuged
at 12,000 rpm for 20 minutes, the supernatant was aspirated, and
an equal amount of 6N NaOHwas added for hydrolysis. Chloromine
T mix (35 mg with 500 mL water) and 100 mL hydrolysate were
mixed with 400 mL acetate/citrate buffer. The samples and stan-
dard hydroxyproline were added to 25 mL of the mixed solution.
Diaminobenzidine (0.33 g) with 500 mL 60% HClO4 were added to
the solution, then 500 mL was mixed with 1.5 mL isopropanol. The
sample and standard hydroxyproline were added to 150 mL of the
mixed solution, placed at 60C for 35 minutes, then cooled for 10
minutes at room temperature. A 540 nm spectrophotometer was
used to measure absorbance values. Hydroxyproline was used as a
standard for calculating hydroxyproline content with a calibration
curve.
Histological assessment
Mice were anesthetized with 2,2,2-tribromoethanol and sacri-
ﬁced with KCl. Extirpated livers were ﬁxed in 4% paraformaldehyde
(Sigma) for 3 days. The livers were embedded in methyl-
methacrylate and sectioned longitudinally utilizing a Leica/Jung
2255 microtome (Leica, Wetzlar, Germany) at a thickness of 5 mm
for pathological section assessment. Frozen sections were used for
donor cell localization. EGFP-mAFSC-transplanted livers were
removed and soaked in 4% paraformaldehyde at 4C for 1 day.
Samples were washed three times in PBS, then immersed in 5%,
10%, and 20% sucrose at 4C for 10 minutes each. The samples were
then put in optimal cutting temperature compound (OCT) (Tissue-
Tek 00004348-01; Houston, TX, USA) at 4C overnight. Frozen
sections were cut at a thickness of 10 mm.
Masson trichrome staining
The biopsy specimen sectionswere dewaxedwith xylene (Sigma
62190) and rehydrated in an alcohol series (100%, 95%, 90%, 80%, and
70%). Bouin solution (SigmaHT10132)wasused toﬁx the sections for
15 minutes, and the sections were washed inwater until the yellow
color was gone. Then, the sections were stained for 10 minutes in
Weigert's iron hematoxylin (Sigma HT1079) and the sections were
rinsed in water for 5 minutes. The sections were then stained with
Biebrich scarlet-acid fuchsin solution (Sigma HT15-1) for 5 minutes
and rinsed with water for 5 minutes. Phosphomolybdicephospho-
tungstic acid solution (Sigma HT15-2,15-3) was utilized to stain the
sections for 5 minutes, washed in water, and immersed in 1% acetic
acid solution (Merck 100058, Darmstadt, Germany) for 2 seconds.
Subsequently, 95% and 100% alcohol was used to dehydrate the
sections for 2 seconds. Finally, the sections were twice immersed in
xylene for 2 minutes and mounted for later observation.
Statistical analysis
The experimental data were analyzed using Student’s t test. The
data are shown as the mean ± standard deviation (SD). A p value
<0.05 indicated a signiﬁcant difference between the groups.
Results
Establishment of mAFSCs
We successfully collected mAFSCs from amniotic ﬂuid and these
cells expressed Sca-1 and CD44 (progenitor/stem cells markers);
Fig. 2. Characterization of mAFSCs. mAFSCs cells (A) can give rise to adipocytes, which are stained by oil red O (B), osteoblasts, which are stained by alizarin red S (C), and
chondrocytes, which are stained by toluidine blue for glycosaminoglycan (D). These cells express stem cell related marker, Sca-1 (E) and CD-44 (F) and cannot express endothelial
cell marker, CD-105 (G). Scale bar represent 50 mm. mAFSCs ¼ mouse amniotic-ﬂuid-derived stem cells.
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mAFPCs gave rise to osteoblasts, adipocytes, and chondrocytes
(Fig. 2).
Mouse weight
Liver ﬁbrosis leads to a metabolic disorder and causes weight
loss. Four weeks after transplanting mAFSCs (16-week-old mice),
the weight signiﬁcantly increased compared to the CCl4 and PBS
groups (mAFPCs, 41.05 ± 2.31 g; PBS, 29.58 ± 2.99 g; and CCl4,
32.33 ± 6.25 g; p < 0.05) (Fig. 3).
Hepatic function improved after mAFSCs transplantation
GOT, GPT and ALB serve as indices of liver health. After treat-
ment with CCl4 for 4 weeks, levels of GOT (8-week-old mice,
49.37 ± 6.94 U/L; 12-week-old mice; 302.66 ± 66.94 U/L; p < 0.05),
GPT (8-week-old mice; 29.55 ± 4.39 U/L; 12-week-old mice,Fig. 3. Comparative analysis of the weight variations of WT mice, CCl4-treated mice,
PBS-injected mice, and mAFSC-transplanted mice. The weight of mAFSC-treated mice
increased signiﬁcantly compared to the CCl4- and PBS-treated groups, and near to the
WT group. Data are presented as the mean of six mice per group and were analyzed
using the Student t test (*p < 0.05; **p < 0.001). mAFSC ¼ mouse amniotic-ﬂuid-
derived stem cell; PBS ¼ phosphate-buffered saline; WT ¼ wild type.706.0 ± 176.83 U/L; p < 0.05); and ALB (8-week-old mice;
1.92 ± 0.11 g/dL; 12-week-old mice, 2.55 ± 0.21 g/dL; p < 0.05) were
signiﬁcantly increased (Fig. 4). Blood was collected 2 weeks and 4
weeks after cell transplantation (14-week-old and 16-week-old
mice, respectively) and serum was obtained to determine the GOT,
GPT and ALB levels. Twoweeks after cell transplantation (14-week-
old mice), the outcomes revealed that the GOT (mAFSCs,
140.50 ± 36.00 U/L; PBS, 400.75 ± 129.75 U/L; p < 0.05), GPT
(mAFSCs, 109.33 ± 60.53 U/L; PBS, 688.75 ± 210.35 U/L; p < 0.05),
and ALB levels (mAFSCs, 2.08 ± 0.11 g/dL; PBS, 2.50 ± 0.18 g/dL;
p < 0.05) were dramatically decreased. Four weeks after cell
transplantation (16-week-old mice), the levels of GOT (mAFSCs,
67.66 ± 13.57 U/L; PBS, 460.60 ± 125.37 U/L; p < 0.05), GPT
(mAFSCs, 52.66 ± 15.21 U/L; PBS, 687.60 ± 165.98 U/L; p < 0.05),
and ALB (mAFSCs, 1.91 ± 0.13 g/dL; PBS, 2.52 ± 0.18 g/dL; p < 0.05)
were signiﬁcantly decreased also (Fig. 4).
Comparison of hydroxyproline content
Collagen is mainly composed of 14% hydroxyproline, which is
rare in other tissues. Thus, hydroxyproline is considered an optimal
index for measuring the collagen content. Sixteen-week-old mice
were sacriﬁced and liver tissues were collected for detection of
collagen content and ﬁbrotic scar tissues in the livers using a
collagen quantiﬁcation reagent (Biovision 61255; London, UK). The
results demonstrate that after treatment with CCl4 for 4 weeks, the
hydroxyproline content was signiﬁcantly higher than in the wild-
type control group treated with oil (CCl4, 126.10 ± 20.66; wild-
type control, 52.06 ± 6.50; p < 0.05) (Fig. 5). Subsequently, treat-
ment with mAFSCs after 4 weeks, the hydroxyproline content was
signiﬁcantly lower than the PBS treatment group (mAFSCs,
73.42 ± 15.95; PBS, 130.166 ± 19.09; p < 0.05). Thus, mAFSC repair
of liver ﬁbrotic tissues can be assessed by hydroxyproline content;
however, the hydroxyproline content of the mAFSC group was
higher than in the wild-type control mice (mAFSCs, 73.42 ± 15.95;
wild-type control; 52.06 ± 6.50; p < 0.05) (Fig. 5).
Masson's trichrome staining and immunoﬂuorescence study showed
the improvement of ﬁbrosis and engraftment in the liver
Liver ﬁbrosis is an intermediate pathological stage during
development of chronic liver disease. Liver tissues undergo
Fig. 4. Biochemical analysis of hepatic function before and after transplantation of mAFSCs in blood serum of liver ﬁbrosis mice. (A) GOT concentration. (B) GPT concentration. (C)
ALB secretion. AFSC-treated mice had signiﬁcantly lower levels than the control group in all measurements of liver injury markers during the 4 weeks after cell transplantation. Data
are presented as the mean ± standard deviation of six mice per group and were analyzed by Student’s t test (*p < 0.05). ALB ¼ albumin; GOT ¼ glutamic oxaloacetic transaminase;
GPT ¼ glutamic pyruvic transaminase; mAFSCs ¼ mouse amniotic-ﬂuid-derived stem cells
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Collagens and ﬁbrotic scar tissues replace injured liver tissues and
cause portal hypertension to enhance the oxidative pressure in the
hepatocytes, resulting in cell death. To assess the severity of liver
ﬁbrosis, Masson’s trichrome staining was used to measure the
content of ﬁbrotic tissue. Continuous liver injury causes accumu-
lation of the ECM and leads to the consequence of ﬁbrotic scar
formation. Fibrotic scar is mainly composed of collagen and appears
blue in Masson’s trichrome staining sections. The results indicate
that 4 weeks after mAFSC transplantation in mice with liver
ﬁbrosis, the ﬁbrotic region is dramatically decreased compared to
the PBS treatment group (Fig. 6). Furthermore, immunoﬂuores-
cence study demonstrated the merge of donor cells in the liver of
recipient after transplantation (Fig. 7).Fig. 5. The hydroxyproline concentration in the livers of WT mice, CCl4-treated mice,
PBS-injected mice, and mAFSC-transplanted mice 4 weeks after transplantation. CCl4
treatment elevated the hydroxyproline concentration. AFSC-transplanted mice
expressed signiﬁcantly lower hydroxyproline than the PBS-treated group. Data are
presented as the mean ± standard deviation of six mice per group and analyzed by
Student’s t test (**p < 0.001). mAFSC ¼ mouse amniotic-ﬂuid-derived stem cell;
PBS ¼ phosphate-buffered saline; WT ¼ wild type.Discussion
The purpose of the present study was to establish whether
EGFP-mAFSCs can repair lesions using chronic liver disease as a
model. We also intended to determine the mechanism by which
cells repair the liver injury site. We used CCl4 to induce liver
ﬁbrosis. CCl4 was dissolved in chloroform, which was delivered to
the liver via blood vessels and resulted in impairment of protein
synthesis, disorders of lipid metabolism, accumulation of reactive
oxygen species, hepatic stellate cell transfer to myoﬁbrolasts, and
secretion of ECM to replace the injured liver gap for maintenance of
liver structure. Accumulation of a large amount of ECM in the liver
is termed ﬁbrosis, which is part of the process of chronic liver
disease. A single, high dose of CCl4 mimics acute liver damage;
multiple injections of mediumelow doses of CCl4 mimic chronic
liver damage. Mice were treated twice weekly with CCl4 (2 mg/kg).
GOT and GTP are speciﬁc aminotransferases in hepatocytes
involved in amino acid metabolismwhich are released in the blood,
whereas rupture of hepatocytes occurs in liver injury. ALB is a
protein secreted by hepatocytes. If the liver is injured, hepatocytes
may perish and compensatory function occurs, which increases the
concentration of ALB. GOT and GPT increased after 4 weeks of CCl4
treatment, indicating that hepatocytes perished, leading to cross-
bridges and ﬁbrotic scar formation. The outcomes are consistent
with mid-term ﬁbrosis (Ishak score ¼ 3e4) [22]. EGFP-mAFSCs
were successfully derived from EGFP-bearing, transgenic 13.5-day
mice. According to the biochemistry analysis, treatment with
EGFP-mAFSCs signiﬁcantly decreased the serum concentrations of
GOT, GPT and ALB. The hydroxyproline concentration in a liver
ﬁbrosis mouse model was also reduced after mAFSC trans-
plantation. The weight records further support the healthy recov-
ery of cell-transplanted mice. All the results mentioned above
suggest that allogeneic AFSC transplantation can efﬁciently
ameliorate liver injury.
Various sources of stem cells have been certiﬁed to give rise to
three germ layer cells in vitro, not only in morphology differentia-
tion, but also in functional characteristics. It remains controversial
whether or not donor cells affect differentiation directly, by fusion,
or a paracrine effect in vivo. Therefore, some researchers have uti-
lized a gender mismatch approach (ﬂuorescence in situ hybridiza-
tion) to determine cell destiny and observed cell fusion in
hepatocytes [23] and intestinal cells [24,25], and further addressed
that reprogramming factors, which enable terminal differentiated
cell reprogramming in the cytoplasm to an earlier stage for regen-
erating and repairing the injured site. It is difﬁcult to determine cell
fate because fusion of cells undergoes somatic cellmeiosis to discard
Fig. 6. Masson's trichrome was stained for the liver ﬁbrosis sections. The blue color represented the ﬁbrotic area. (A) Mice transplanted with mouse amniotic-ﬂuid-derived stem
cells; (B) mice treated with phosphate-buffered saline (100).
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ﬂuorescent colors to investigate cell fate in vivo (EFGP for donor cells
and Ds-red for recipient cells), which are ubiquitously expressed in
the entire mouse body. Our histological data revealed that EGFP-
AFSCs were successfully engrafted to the liver through the mesen-
tery, were capable of fusingwith the Ds-red recipient liver cells, and
eventually appeared yellow in color. Nuclear respiratory factors
(Nrf)2 transcription factor can protect liver ﬁbrosis by reducing
oxidative-stress-induced apoptosis [27,28]. It has been shown thatFig. 7. Liver ﬁbrosis sections for detecting colocalization of the donor cells (EGFP-mAFPC
represents 4,6-diamidino-2-phenylindole (DAPI) staining for the nucleus. (B) Liver section o
EGFP-mAFPCs were distributed around the liver blood vessels, which are shown in green. (D
(liver of ds-red mice) (400). EGFP ¼ enhanced green ﬂuorescent protein; mAFSCs ¼ moudonor cells can express matrix metallopeptidases to improve liver
ﬁbrosis [29]. Donor cells can fusewith recipient cells and these cells
engage in transcription and reprogramming factor exchange in the
cytoplasm or nucleus for repairing lesion sites [26]. Furthermore,
the tumor necrosis factor receptor-1 signaling pathway may be
involved in reversing liver ﬁbrosis [30]. Hence, we assume that
recipient liver cell exchange transcription or reprogramming factor
or enzymes from EGFP-AFSCs through fusion to repair the liver
ﬁbrosis model is consistent with a previous study [23].s) merged with recipient cells after transplantation for 48 hours. (A) The blue color
f ds-red transgenic mice revealed ubiquitous expression of red ﬂuorescent protein. (C)
) Yellow color indicates the merging of donor cells (EGFP-mAFPCs) and recipient cells
se amniotic-ﬂuid-derived stem cells.
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the liver ﬁbrosis recipient without immune rejection and efﬁciently
ameliorated the syndrome of liver ﬁbrosis [4,31,32]. With respect to
AFSCs for future clinical trials, amniotic-ﬂuid-derived cells are early
embryonic cells that are shed from the growing fetus and can be
collected during the second trimester of pregnancy through
amniocentesis and stored long term for future autotransplantation
without the risk of immune rejection.
In addition, it has been demonstrated that combining ﬁbroblast
growth factor 2 [33] or NO [34] with donor cells and expression of
androgen receptor on donor cells [35] can efﬁciently ameliorate the
liver ﬁbrosis syndrome. As a result, in the future we may treat with
ﬁbroblast growth factor 2 or NO, or overexpress androgen receptor
to investigate further the efﬁcacy of mAFSCs in liver ﬁbrosis.
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